Compare Cytokinetics Inc (CYTK) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Wix.Com Ltd — how do they compare? Cytokinetics Inc trades at $82.13 (market cap $11.12B), while Wix.Com Ltd trades at $53.14 (market cap $2.21B). The key difference: Cytokinetics Inc is far larger — about 5× Wix.Com Ltd's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| CYTK | WIX | |
|---|---|---|
Market Cap | $11.12B | $2.21B |
Sector | Technology | Technology |
52-Week High | $87.26 | $184.24 |
52-Week Low | $33.23 | $40.43 |
Enterprise Value | $11.59B | $1.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Wix trades at $52.41, up 4.53% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue grew to $1.99B in 2025, though net income fell to $50.65M, and the stock carries a high P/E of 62.84. Recent news highlights AI-related volatility and a partnership with Elavon to enhance small business payments.
The outlook is mixed: strong analyst consensus (67.5% buy ratings) and a $83.13 price target suggest upside, but risks include legal investigations, expense spikes, and negative shareholder equity. Earnings misses in Q1 2026 and high valuation metrics warrant caution despite growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
